Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex.

Aldape RA, Futer O, DeCenzo MT, Jarrett BP, Murcko MA, Livingston DJ.

J Biol Chem. 1992 Aug 15;267(23):16029-32.

2.
3.

Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex.

Kissinger CR, Parge HE, Knighton DR, Lewis CT, Pelletier LA, Tempczyk A, Kalish VJ, Tucker KD, Showalter RE, Moomaw EW, et al.

Nature. 1995 Dec 7;378(6557):641-4.

PMID:
8524402
4.

X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex.

Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA.

Cell. 1995 Aug 11;82(3):507-22.

5.
6.
7.

Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex.

Wiederrecht G, Hung S, Chan HK, Marcy A, Martin M, Calaycay J, Boulton D, Sigal N, Kincaid RL, Siekierka JJ.

J Biol Chem. 1992 Oct 25;267(30):21753-60.

8.

A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor.

Lam E, Martin MM, Timerman AP, Sabers C, Fleischer S, Lukas T, Abraham RT, O'Keefe SJ, O'Neill EA, Wiederrecht GJ.

J Biol Chem. 1995 Nov 3;270(44):26511-22.

9.

Solution structure of FK506 bound to the R42K, H87V double mutant of FKBP-12.

Lepre CA, Pearlman DA, Cheng JW, DeCenzo MT, Livingston DJ, Moore JM.

Biochemistry. 1994 Nov 22;33(46):13571-80.

PMID:
7524662
10.

Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin.

Tamura K, Fujimura T, Iwasaki K, Sakuma S, Fujitsu T, Nakamura K, Shimomura K, Kuno T, Tanaka C, Kobayashi M.

Biochem Biophys Res Commun. 1994 Jul 15;202(1):437-43.

PMID:
7518678
11.
12.
13.
14.
15.

FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition.

Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, Bourgeois S.

Mol Cell Biol. 1995 Aug;15(8):4395-402.

16.

FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes.

DeCenzo MT, Park ST, Jarrett BP, Aldape RA, Futer O, Murcko MA, Livingston DJ.

Protein Eng. 1996 Feb;9(2):173-80.

PMID:
9005438
17.

Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes.

Clipstone NA, Fiorentino DF, Crabtree GR.

J Biol Chem. 1994 Oct 21;269(42):26431-7.

18.

FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.

Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE.

Eur J Immunol. 1995 Feb;25(2):563-71.

PMID:
7533090
19.

Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast.

Hemenway CS, Heitman J.

J Biol Chem. 1996 Aug 2;271(31):18527-34.

20.

Calcineurin mutants render T lymphocytes resistant to cyclosporin A.

Zhu D, Cardenas ME, Heitman J.

Mol Pharmacol. 1996 Sep;50(3):506-11.

PMID:
8794888

Supplemental Content

Support Center